ALPMY News and Press, Astellas Pharma Inc. ADR From 02/19/23

Astellas Provides Update on Fezolinetant New Drug Application in U.S. PR Newswire TOKYO , Feb. 19, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced the U.S. Food and Drug Administrati...

Summary Astellas came in with a mixed set of results, with growth across product segments balanced by challenges in U.S. sales. We are unsure about generic competitors posing a threat to XTANDI's market share. Profitability and economic profit continue to remain a standout, despite ...

Astellas Commits to Achieve Net Zero Greenhouse Gas Emissions by 2050 PR Newswire TOKYO , Feb. 9, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced its commitment to achieve net z...

The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2023 Q3 earnings call. For further details see: Astellas Pharma Inc. 2023 Q3 - Results - Earnings Call Presentation

Summary Taysha has a good chance of scoring with the GAN indication. Astellas may license this program if that happens. However, the FDA's request for more patients is a critical problem. Since its IPO in September 2020, Taysha Gene Therapies ( TSHA ) stock price has b...

Astellas Pharma ( OTCPK:ALPMY ) said that Naoki Okamura will take over as new President and CEO, effective April 1, 2023. He replaced Kenji Yasukawa who will now take the position of representative director and chairman of the Board. Okamura currently serves the representativ...

Astellas Announces Change of President and CEO and Management Structure PR Newswire TOKYO , Feb. 5, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced that at a meeting of its Boar...

Novartis' ( NYSE: NVS ) Sandoz is acquiring worldwide product rights to Astellas Pharma's ( OTCPK:ALPMY ) ( OTCPK:ALPMF ) antifungal drug Mycamine. Mycamine belongs to a class of antifungal drugs called echinocandins. The drugs is used as a preventive thera...

Astellas Transfers MYCAMINE® Product Worldwide PR Newswire TOKYO , Jan. 23, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced that Astellas and Sandoz AG ("Sandoz") have entered i...

Astellas Pharma ( OTCPK:ALPMY ) ( OTCPK:ALPMF ) said the U.S. Food and Drug Administration (FDA) lifted a clinical hold on a trial of its gene replacement therapy AT845 to treat adults with late-onset Pompe disease (LOPD). The FDA had placed a hold on the phase 1/2 t...